Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Hepatocellular Carcinoma: Future Directions in Care

October 23rd 2019

Perioperative Approaches to HCC Management

October 23rd 2019

Optimal Sequencing of I/O Therapy in Liver Cancer

October 23rd 2019

I/O Combination Strategies in Hepatocellular Carcinoma

October 23rd 2019

Elevated AFP in Relapsed/Refractory Metastatic HCC

October 23rd 2019

Optimal Use of Second-Line TKIs in Hepatocellular Carcinoma

October 23rd 2019

Hepatocellular Carcinoma: Antiangiogenic Therapy Options

October 23rd 2019

Implications for I/O Therapy in the Treatment of HCC

October 23rd 2019

Liver Pathobiology's Role in Hepatocellular Carcinoma

October 23rd 2019

Final Thoughts on Targeted Therapy and I/O Agents in NSCLC

October 18th 2019

Tumor Mutational Burden in Key Phase III Trials of NSCLC

October 18th 2019

Role of Tumor Mutational Burden in NSCLC

October 18th 2019

CASPIAN Trial: Durvalumab and Chemotherapy in ES-SCLC

October 18th 2019

I/O + Chemotherapy in Treatment-Naive ES-SCLC

October 18th 2019

Long-Term Outcomes With PD-1 Monotherapy in NSCLC

October 18th 2019

Role of I/O With Chemotherapy in Advanced Squamous NSCLC

October 18th 2019

CheckMate 817 Dual Immune-Checkpoint Inhibition in ECOG PS 2

October 18th 2019

CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLC

October 18th 2019

Targeted Therapy for KRAS-Mutant NSCLC

October 18th 2019

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

October 18th 2019